You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
DBL Gemcitabine Injection is indicated: 1. For treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 2. For treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. 3. For treatment of patients with FU refractory pancreatic cancer. 4. Alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. 5. In combination with paclitaxel, for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. 6. In combination with carboplatin, for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
DBL Gemcitabine Injection is indicated: 1. For treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 2. For treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. 3. For treatment of patients with FU refractory pancreatic cancer. 4. Alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. 5. In combination with paclitaxel, for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. 6. In combination with carboplatin, for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
DBL Gemcitabine Injection is indicated: 1. For treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 2. For treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. 3. For treatment of patients with FU refractory pancreatic cancer. 4. Alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. 5. In combination with paclitaxel, for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. 6. In combination with carboplatin, for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
